Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor κb

Hypertension

Volumn 55, Issue 4, 2010, Pages 924-931

  Rompe, Franziska ^a   Artuc, Metin ^a   Hallberg, Anders ^b   Alterman, Mathias ^b   Ströder, Katja ^a   Thöne Reineke, Christa ^a   Reichenbach, Anne ^a   Schacherl, Jens ^a   Dahlöf, Björn ^c   Bader, Michael ^d   Alenina, Natalia ^d   Schwaninger, Markus ^e   Zuberbier, Torsten ^a   Funke Kaiser, Heiko ^a   Schmidt, Cosima ^d   Schunck, Wolf Hagen ^d   Unger, Thomas ^a   Steckelings, U Muscha ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UPPSALA UNIVERSITY   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiotensin; AT2 receptor; Drug development; Inflammation; NF B

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; BLEOMYCIN; COMPOUND 21; CYTOKINE; EPOXYICOSATRIENOIC ACID; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; PHOSPHOPROTEIN PHOSPHATASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DIHOMO GAMMA LINOLENIC ACID; MESSENGER RNA; N BUTYLOXYCARBONYL 3 (4 IMIDAZOL 1 YLMETHYLPHENYL) 5 ISOBUTYLTHIOPHENE 2 SULFONAMIDE; N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1-YLMETHYLPHENYL)-5-ISOBUTYLTHIOPHENE-2-SULFONAMIDE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HORMONAL REGULATION; HORMONE INHIBITION; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SKIN INFLAMMATION; ANIMAL; CELL CULTURE; CELL NUCLEUS; CYTOLOGY; DOSE RESPONSE; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENETICS; INFLAMMATION; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; CELL NUCLEUS; CELLS, CULTURED; CHEMOKINE CCL2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; HUMANS; INFLAMMATION; INTERLEUKIN-6; MICE; NF-KAPPA B; RECEPTOR, ANGIOTENSIN, TYPE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFONAMIDES; THIOPHENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950472601     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.147843     Document Type: Article

References (31)

1. Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704-2715.
2. Higgs DR. A new dawn for stem cell therapy. N Engl J Med. 2008;358: 964-966.
3. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International Union of Pharmacology: XXIII-the angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
4. Steckelings UM, Kaschina E, Unger T. The AT2-receptor: a matter of love and hate. Peptides. 2005;26:1401-1409.
5. Volpe M, Musumeci B, De Paolis P, Savoia C, Morganti A. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens. 2003;21:1429-1443.
6. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, Sakanaka M, Shiuchi T, Horiushi M. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation. 2004;110: 843-848.
7. Bove CM, Gilson WD, Scott CD, Epstein FH, Yang Z, Dimaria JM, Berr SS, French BA, Bishop SP, Kramer CM. The angiotensin II type 2 receptor and improved adjacent region function post-MI. J Cardiovasc Magn Reson. 2005;7:459-464.
8. Iwai M, Chen R, Li Z, Shiuchi T, Suzuki J, Ide A, Tsuda M, Okumura M, Min L-J, Mogi M, Horiushi M. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation. 2005;112:1636-1643.
9. Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med. 1998;188:661-670.
10. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-657.
11. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlen A, Pettersson A, Nyberg F, Fändriks L, Gallo-Payet N, Hallberg A, Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995-6008.
12. Takagawa S, Lakos Mori Y, Yamamoto T, Nishioka K, Varga J. Sustained activation of fibroblast transforming growth factor-/3/Smad signaling in a murine model of scleroderma. J Invest Dermatol. 2003;121: 41-50.
13. Wu L, Iwai M, Li Z, Shiuchi T, Min L-J, Cui T-X, Li J-M, Okumura M, Nahmias C, Horiuchi M. Regulation of inhibitory protein-?B and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol Endocrinol. 2004;18:666-678.
14. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JM. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285:1276-1279.
15. Morisseau C, Hammock BD. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol. 2005;45: 311-333.
16. Kroetz DL, Xu F. Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol. 2005;45:413-438.
17. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:31-85.
18. Horiuchi M, Hayashida W, Akishita M, Tamura K, Daviet L, Lehtonen JY, Dzau VJ. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ Res. 1999;84:876-882.
19. Tani T, Ayuzawa R, Takagi T, Kanehira T, Maurya DK, Tamura M. Angiotensin II bi-directionally regulates cyclooxygenase-2 expression in intestinal epithelial cells. Mol Cell Biochem. 2008;315:185-193.
20. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003;140: 809-824.
21. Ichihara S, Senbonmatsu T, Price Jr E, Ichiki T, Gaffney FA, Inagami T. Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction. Circulation. 2002;106:2244-2249.
22. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BML, Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type 2 receptor. Nature. 1995;377:748-750.
23. Tsuzuki S, Matoba T, Eguchi S, Inagami T. Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. Hypertension. 1996;28:916-918.
24. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck P, Tschöpe C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf K, Dahlöf B, Kintscher U, Unger T, Steckelings UM. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin-system in myocardial infarction? Circulation. 2008;118:2523-2532.
25. Tian Q, Miyazaki R, Ichiki T, Imayama I, Inanaga K, Ohtsubo H, Yano K, Takeda K, Sunagawa K. Inhibition of tumor necrosis factor-α-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-γ with nuclear factor kappaB and CCAAT/enhancer-binding protein-/3. Hypertension. 2009;53:798-804.
26. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14:109-119.
27. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619-622.
28. D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B: An emerging theme in anti-inflammatory therapies. Mol Interv. 2002;2: 22-35.
29. Sethi G, Sung B, Aggarwal BB. Nuclear factor-?B activation: from bench to bedsite. Exp Bio Med. 2008;233:21-31.
30. Gelosa P, Pignieri A, Fändriks L, de Gasparo M, Hallberg A, Banfi C, Castiglioni L, Turolo L, Guerrini U, Tremoli E, Sironi L. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444-2451.
31. Ruilope LM, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S, Unger T, Volpe M, Waeber B, Zannad F. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press. 2005;14: 196-209. (Pubitemid 41387809)